Even triple combinations with low-dose cytarabine, azacytidine and cladribine [38] or venetoclax, decitabine and FLT3-inhibitors [39,40] are currently under investigation as front-line therapy for unfit elderly with AML. Here, FLT3 is linked to acute myeloid leukemia.